Last Updated: November 16, 2026

Investigational Drug Information for Prexasertib

« Back to Dashboard


What is the development status for investigational drug Prexasertib?

Prexasertib is an investigational drug.

There have been 19 clinical trials for Prexasertib. The most recent clinical trial was a Phase 2 trial, which was initiated on September 25th 2024.

The most common disease conditions in clinical trials are Neoplasms, Leukemia, Myeloid, and Syndrome. The leading clinical trial sponsors are Eli Lilly and Company, Dana-Farber Cancer Institute, and National Cancer Institute (NCI).

There are ninety-five US patents protecting this investigational drug and one hundred and seventy-one international patents.

Recent Clinical Trials for Prexasertib
TitleSponsorPhase
A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCCAcrivon TherapeuticsPHASE2
A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCCH. Lee Moffitt Cancer Center and Research InstitutePHASE2
A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial CarcinomaGOG FoundationPhase 1/Phase 2

See all Prexasertib clinical trials

Clinical Trial Summary for Prexasertib

Top disease conditions for Prexasertib
Top clinical trial sponsors for Prexasertib

See all Prexasertib clinical trials

US Patents for Prexasertib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Prexasertib ⤷  Start Trial Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) ⤷  Start Trial
Prexasertib ⤷  Start Trial 5-(5-(2-(3-aminopropdoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2- -carbonitfile (S)-lactate monohydrate Eli Lilly and Company (Indianapolis, IN) ⤷  Start Trial
Prexasertib ⤷  Start Trial Targeted therapeutics MADRIGAL PHARMACEUTICALS, INC. (West Conshohocken, PA) ⤷  Start Trial
Prexasertib ⤷  Start Trial PD-1/PD-L1 inhibitors Gilead Sciences, Inc. (Foster City, CA) ⤷  Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Prexasertib

Drugname Country Document Number Estimated Expiration Related US Patent
Prexasertib Australia AU2017261372 2036-05-05 ⤷  Start Trial
Prexasertib Canada CA3023278 2036-05-05 ⤷  Start Trial
Prexasertib China CN107847398 2036-05-05 ⤷  Start Trial
Prexasertib European Patent Office EP3452003 2036-05-05 ⤷  Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Prexasertib Development Update and Market Projection

Last updated: November 11, 2026

Prexasertib, Eli Lilly’s intravenous checkpoint kinase 1 inhibitor, has no FDA approval, no commercial sales, and no established launch date. Public development has centered on recurrent ovarian cancer, triple-negative breast cancer, and other advanced solid tumors. The clinical profile showed antitumor activity, but severe hematologic toxicity, intravenous administration, and the absence of a validated biomarker have limited commercial prospects. The base-case market projection is $0 through the near term unless a sponsor restarts development and generates positive randomized data.

What is the current development status of prexasertib?

Prexasertib, also known as LY2606368, is a selective small-molecule CHK1 inhibitor administered by intravenous infusion. CHK1 regulates DNA-damage response and cell-cycle progression. Inhibition is intended to increase replication stress and drive tumor-cell death, particularly in tumors with defective DNA-repair pathways.

Eli Lilly has been the principal developer. Prexasertib has not reached a registrational Phase 3 program or an FDA filing based on the public clinical record.

Attribute Prexasertib status
Generic name Prexasertib
Development code LY2606368
Drug class Selective CHK1 inhibitor
Modality Small molecule
Administration Intravenous
Lead developer Eli Lilly and Company
FDA approval None
Commercial status Not marketed
Orange Book listing None
Confirmed launch date None
Principal clinical focus Recurrent ovarian cancer and advanced solid tumors
Main development risk Myelosuppression, especially neutropenia

Clinical studies have evaluated prexasertib as monotherapy and in combinations with DNA-damaging agents. Publicly reported work has included recurrent BRCA-wild-type high-grade serous ovarian cancer, triple-negative breast cancer, pediatric solid tumors, and other refractory malignancies. ClinicalTrials.gov records indicate that several studies have been completed, terminated, or otherwise lack evidence of progression toward registration. [1]

What clinical data support prexasertib?

The strongest efficacy signal came from a Phase 2 study in recurrent BRCA-wild-type high-grade serous ovarian cancer. The study evaluated prexasertib in patients with heavily pretreated disease, including patients whose tumors lacked BRCA mutations.

Published results reported an objective response rate of approximately 29% in the evaluable population, with responses observed despite extensive prior treatment. Median progression-free survival was approximately four months. The activity was clinically relevant for a population with limited options, but the study was small, single-arm, and insufficient to establish comparative benefit. [2]

Key ovarian-cancer data

Metric Reported result
Disease setting Recurrent BRCA-wild-type high-grade serous ovarian cancer
Study type Phase 2, single-arm
Objective response rate Approximately 29%
Median progression-free survival Approximately 3.7 months
Key safety issue Grade 3/4 neutropenia
Route Intravenous

The response signal did not establish that CHK1 inhibition improves overall survival or progression-free survival compared with approved therapies. The development case also faced competition from poly(ADP-ribose) polymerase inhibitors, antibody-drug conjugates, platinum rechallenge, and other targeted therapies.

In triple-negative breast cancer, prexasertib was investigated because the disease often has high replication stress and limited targeted treatment options. Available public data have not shown a clinical benefit sufficient to support a regulatory filing. The same limitation applies to other exploratory tumor types.

How strong is the prexasertib clinical profile?

Prexasertib has a credible biological mechanism and demonstrated monotherapy activity. Its clinical profile is weaker as a commercial asset because the efficacy evidence is derived mainly from early-stage, nonrandomized studies.

Positive development factors

  • Activity was reported in heavily pretreated ovarian cancer.
  • The mechanism is relevant to tumors with replication stress and DNA-repair defects.
  • Responses were reported in BRCA-wild-type disease, where treatment options remain differentiated from BRCA-directed strategies.
  • CHK1 inhibition could potentially be combined with chemotherapy, PARP inhibitors, or other DNA-damage therapies.

Negative development factors

  • Neutropenia was frequent and clinically significant.
  • Intravenous dosing creates a higher treatment burden than oral targeted therapies.
  • No predictive biomarker has been clinically validated.
  • The evidence has not demonstrated superiority or a durable benefit against modern standards of care.
  • Combination strategies may increase overlapping marrow toxicity.
  • The program has not produced a late-stage registration path.

The central development question is whether a biomarker-selected population can produce a sufficiently large therapeutic window. Without that evidence, prexasertib competes as an intravenously administered cytotoxic-like targeted agent in a market increasingly favoring oral drugs, antibody-drug conjugates, and biomarker-defined therapies.

What is the FDA regulatory status of prexasertib?

Prexasertib is not FDA-approved and has no established FDA exclusivity period. It does not have a New Drug Application approval, a Biologics License Application, or an approved indication listed by FDA.

The drug has no approved-label status under the Federal Food, Drug, and Cosmetic Act. There is no public basis to assign a Prescription Drug User Fee Act action date or a commercial launch window.

Orange Book status

Prexasertib is not listed as an FDA-approved drug product in the Orange Book. As a result:

  • There is no Orange Book-listed patent for an approved prexasertib product.
  • There is no Orange Book reference-listed drug.
  • Abbreviated New Drug Application applicants cannot file Paragraph IV certifications against a marketed prexasertib product.
  • No approved-product patent litigation framework currently applies.

Clinical-trial patents or pending patent applications may exist, but they do not create FDA Orange Book protection unless associated with an approved product and listed under FDA rules. [3]

When does prexasertib lose exclusivity?

Prexasertib has no FDA-granted market exclusivity because it has not been approved. Any patent protection must be analyzed separately by patent family, jurisdiction, claim scope, terminal disclaimers, patent-term adjustment, and maintenance status.

Public clinical development materials identify prexasertib as LY2606368, but the commercial value of any composition-of-matter or method-of-use patents is limited by the absence of an approved product and the apparent lack of active late-stage development.

Exclusivity category Status
FDA approval None
New chemical entity exclusivity Not granted
Orphan-drug exclusivity No established approved indication
Pediatric exclusivity None established
Orange Book patent term None
Paragraph IV exposure No current approved-product pathway
Commercial exclusivity None

A patent expiry date cannot be treated as a launch date. Even if a patent family remains in force, a generic or other developer would still need an approved product, clinical support, manufacturing capability, and a viable regulatory pathway.

What patents protect prexasertib?

Prexasertib’s patent position likely includes research-era patent families covering CHK1 inhibitors, pharmaceutical compositions, and therapeutic uses. The existence of those families does not establish that a particular patent claims prexasertib specifically, remains enforceable, or would block a competing CHK1 inhibitor.

A complete patent assessment would require current records from the USPTO, WIPO, EPO, and national registers, including continuations, divisionals, assignments, prosecution history, patent-term adjustment, and maintenance fees. The available regulatory record does not provide a reliable, consolidated expiration table for prexasertib-specific claims.

Likely protection categories

  • Compound and salt claims
  • Pharmaceutical composition claims
  • Intravenous formulation claims
  • Methods of treating ovarian cancer
  • Methods involving BRCA-wild-type tumors
  • Combination treatment with DNA-damaging agents
  • Dosing schedules intended to manage neutropenia
  • Biomarker-defined patient-selection methods

The most commercially important claims would be valid composition-of-matter claims and enforceable method-of-use claims covering a defined patient population. Formulation and dosing claims would have less value if competitors could use a different formulation, schedule, or route.

Are there Paragraph IV challenges or generic competitors?

No meaningful Paragraph IV challenge has been established because prexasertib lacks an approved reference product and Orange Book listing. There are also no known commercial generic versions.

A future generic challenge would be unlikely unless Lilly or another sponsor first obtained approval. If the compound-of-matter patent had expired by that point, a generic developer could pursue a conventional abbreviated pathway, subject to any remaining formulation or method-of-use patents. If method-of-use claims remained active, a label carve-out could become relevant.

The more realistic competitive threat is not a traditional generic. It is substitution by other DNA-damage-response therapies, including PARP inhibitors, ATR inhibitors, WEE1 inhibitors, platinum agents, and antibody-drug conjugates.

What patent litigation affects prexasertib?

No major public patent litigation involving an approved prexasertib product is established. There is no known Hatch-Waxman litigation record tied to a commercial prexasertib reference product.

Clinical-trial disputes, patent-prosecution disputes, or licensing matters involving CHK1 technology would not automatically affect market entry. The practical litigation risk would rise only if a sponsor revived the program, obtained approval, and listed enforceable patents in the Orange Book.

What is the market projection for prexasertib?

The base-case forecast is no revenue through the near term because prexasertib has no approval, no launch plan, and no visible late-stage program. A commercial forecast based on historical clinical activity alone would overstate its value.

Scenario Development outcome Near-term revenue outlook
Base case Program remains inactive or discontinued $0
Re-entry case Sponsor restarts Phase 2 with biomarker strategy No meaningful revenue before approval
Positive registration case Phase 3 success and FDA approval in ovarian cancer Potential specialty-oncology product
Broad-label case Approval expands into breast and other solid tumors Higher upside, but low probability

A successful relaunch would require several steps:

  1. Identify a predictive biomarker, such as replication-stress or DNA-repair deficiency markers.
  2. Select a disease setting with measurable unmet need.
  3. Establish a tolerable dosing schedule.
  4. Demonstrate benefit against current standard therapy.
  5. Resolve intravenous administration and treatment-center burden.
  6. Secure sufficient intellectual-property protection for the approved use and formulation.

Potential commercial opportunity if revived

The most plausible initial market would be recurrent ovarian cancer, particularly patients with platinum-resistant or BRCA-wild-type high-grade serous disease. That market is clinically meaningful but crowded. A successful product would likely need a differentiated response rate, durable disease control, or a combination benefit that justifies its hematologic toxicity.

The product would face competition from:

  • PARP inhibitors, where patients remain eligible
  • Mirvetuximab soravtansine in folate-receptor-alpha-positive ovarian cancer
  • Platinum-based chemotherapy
  • Weekly paclitaxel
  • Topotecan
  • Pegylated liposomal doxorubicin
  • Other antibody-drug conjugates and DNA-damage-response inhibitors

An approval restricted to a biomarker-defined subgroup could support premium pricing but would limit the addressable population. A broad label would increase revenue potential but require stronger efficacy and safety evidence.

How does prexasertib compare with other CHK1 and DNA-damage-response drugs?

Prexasertib entered a field in which several agents target replication stress, but the competitive standard has moved toward oral dosing and biomarker selection.

Drug or class Target Development/commercial position Relative issue for prexasertib
Prexasertib CHK1 Unapproved clinical candidate Requires development restart and stronger validation
Adavosertib WEE1 Clinical development Similar replication-stress rationale; oral administration may be advantageous
Ceralasertib ATR Clinical development Competes for DNA-damage-response positioning
Olaparib and other PARP inhibitors PARP1/2 Approved in multiple settings Established efficacy and oral dosing
Mirvetuximab soravtansine FR-alpha-directed ADC Approved in ovarian cancer Direct competition in a relevant disease population
Platinum chemotherapy DNA crosslinking Established standard Lower novelty but familiar clinical use

Prexasertib’s differentiation depends on activity in tumors that are resistant to PARP inhibitors and platinum therapy. That is a difficult population because resistance frequently reflects broader DNA-repair adaptation and aggressive disease biology.

What licensing deals involve prexasertib?

Eli Lilly is the publicly identified principal developer. No major out-licensing transaction or commercial co-development agreement has established a current partner with responsibility for prexasertib commercialization.

The absence of a visible licensing transaction is consistent with a program whose commercial value remains unproven. A future deal would likely be structured around a development restart, biomarker rights, or a combination program rather than immediate commercial rights.

What generic launch risks exist for prexasertib?

A conventional generic launch risk is currently low because there is no approved product. If development resumes, risk would shift to patent and regulatory timing.

The main scenarios are:

  • A sponsor obtains approval while composition patents remain active, delaying generic entry.
  • Composition claims expire, but formulation or use patents remain enforceable.
  • A competitor develops a different CHK1 inhibitor and avoids prexasertib claims.
  • A generic files after patent expiry but faces limited demand because the market has moved to competing targeted therapies.
  • A label carve-out permits use outside patented indications.

The commercial risk is therefore more closely tied to clinical obsolescence than to immediate generic substitution.

Key Takeaways

  • Prexasertib is an unapproved intravenous CHK1 inhibitor developed primarily by Eli Lilly.
  • The strongest reported signal was an approximately 29% response rate in a small Phase 2 ovarian-cancer study.
  • Severe neutropenia and the lack of a validated biomarker are major liabilities.
  • There is no FDA approval, Orange Book listing, Paragraph IV litigation, or commercial revenue.
  • No reliable launch date or active late-stage registration program is established.
  • The base-case market projection is $0 in the near term.
  • A viable relaunch would require biomarker selection, improved tolerability, and randomized evidence against modern ovarian-cancer therapies.
  • Competitive pressure comes from PARP inhibitors, antibody-drug conjugates, platinum agents, ATR inhibitors, and WEE1 inhibitors.

FAQs

Is prexasertib still being developed?

Public clinical evidence does not establish an active late-stage development program. The asset remains an unapproved clinical candidate without a confirmed commercial sponsor or launch timeline.

Has prexasertib been approved for ovarian cancer?

No. FDA has not approved prexasertib for ovarian cancer or any other indication.

Is prexasertib an oral drug?

No. Clinical studies have evaluated prexasertib as an intravenous treatment.

Can a generic company launch prexasertib now?

No commercial generic launch pathway is currently available because there is no FDA-approved prexasertib reference product.

What would increase the value of prexasertib?

The strongest value drivers would be a validated biomarker, reduced neutropenia, durable responses in platinum- and PARP-resistant ovarian cancer, and positive randomized data supporting a registrational filing.

References

  1. ClinicalTrials.gov. (n.d.). Studies involving prexasertib (LY2606368). U.S. National Library of Medicine. https://clinicaltrials.gov/

  2. Lee, J. M., et al. (2018). Prexasertib in BRCA wild-type recurrent high-grade serous ovarian cancer: A single-arm phase 2 study. The Lancet Oncology.

  3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

  4. Eli Lilly and Company. (2024). Annual report. https://investor.lilly.com/financial-information/annual-reports-and-proxy-statements

  5. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.